Day: February 5, 2026

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus Group” or “the Company”) (TSX: AIF) announced today it plans to release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after market close on Thursday, February 19, 2026. Altus Group executives Mike Gordon, Chair and Chief Executive Officer (“CEO”), and Pawan Chhabra, Chief Financial Officer, will host a conference call at 5:00 p.m. (ET) the same day to discuss the results. Analysts who wish to ask questions during the call can participate by telephone at 1-888-660-6785 (conference ID: 8366990). A live and archived webcast of the call will be available on the Investor Relations section of the Company’s website at: https://www.altusgroup.com/investor-relations/. The Company also announced that Mike Gordon officially assumed...

– Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the presentation, Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, will provide a corporate overview highlighting the Company’s next-generation antibody drug conjugate platform and proprietary PH1 spliceosome-modulating payload. He will discuss Akari’s lead program, AKTX-101, a Trop2-targeting ADC designed to deliver PH1 directly to tumors with limited off-target...

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, LongeveronThe Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029 The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseases U.S. FDA has awarded Longeveron’s laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation With the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel’s Biological License Application (BLA) is approved by the FDA before September 2029MIAMI, Feb. 05, 2026 (GLOBE NEWSWIRE) —...

– Live video webcast on Wednesday, February 11th at 1:20 PM EST   HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Walter Klemp, Founder, President, CEO and Chairman of MoleculinRegistration Link: Here About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the...

Summit Networks Inc. Announces Revocation of Cease Trade OrderSummit Networks Inc. (OTCQB: SNTW) (the “Company”) announces with great pleasure that the British Columbia Securities Commission (“BCSC”) has issued an order revoking the cease trade order, originally issued in respect of the securities of Company on January 31, 2025.VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) — Summit Networks Inc. (OTCQB: SNTW) (the “Company”) announces that the British Columbia Securities Commission (“BCSC”) has issued an order revoking the cease trade order, originally issued in respect of the securities of Company on January 31, 2025. The cease trade order was issued in connection with the Company’s failure to file certain required annual continuous disclosure documents within the prescribed timeframe. During the relevant...

– Live video webcast on Wednesday, February 11th at 1:00 PM EST  LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows:Date and Time: Wednesday, February 11, 2026 at 1:00 PM ESTPresenter: Marc Hertz, PhD, President, Chief Executive Officer and DirectorRegistration Link: Here About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology....

Celebration, FL, Feb. 05, 2026 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced that it has entered into a contract to purchase a strategically located parcel of land located in Osceola County, one of the fastest-growing areas of Central Florida. This acquisition, once consummated, will represent a major milestone in the Company’s expansion strategy and support the development of a state-of-the-art Tier III AI data center designed to meet rising demand for high-performance computing and data processing infrastructure. The planned facility will encompass up to 10,000 square feet and is expected to support an estimated IT load of ~1,500 kW, making it well-suited for enterprise, cloud, and AI-driven workloads. The proposed data center is intentionally...

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi’s 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, March 38:50AM PT/11:50AM ET Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days. About Allogene TherapeuticsAllogene Therapeutics, with...